When R satisfies (strong unit) 1-stable range and M is a R-R-bimodule, the authors calculate that K_1(R(?) M)≌U(R(?) M)/L(R(?) M). As applications, the authors also calculate some Whitehead groups for exchange rings ...When R satisfies (strong unit) 1-stable range and M is a R-R-bimodule, the authors calculate that K_1(R(?) M)≌U(R(?) M)/L(R(?) M). As applications, the authors also calculate some Whitehead groups for exchange rings with artinian primitive factors.展开更多
背景:纳米材料是抗肿瘤药物的理想载体,具有重要的科学价值和应用价值,为临床抗肿瘤提供了新的有效手段。目的:系统评价纳米给药系统在肿瘤靶向治疗的基础研究及临床应用。方法:以"nanoparticle,cancer,drug delivery system,nanot...背景:纳米材料是抗肿瘤药物的理想载体,具有重要的科学价值和应用价值,为临床抗肿瘤提供了新的有效手段。目的:系统评价纳米给药系统在肿瘤靶向治疗的基础研究及临床应用。方法:以"nanoparticle,cancer,drug delivery system,nanotube,nanosphere"为关键词,计算机检索北美临床试验注册中心及Web of Science数据库2000-01-01/2012-12-31发表的纳米给药系统在肿瘤靶向治疗相关临床试验注册项目及文献。根据纳入与排除标准筛选文献,将检索结果以注册号、注册题目、项目状态、干预措施、试验的申办者、试验的疾病种类导出进行评价质量及文献分析。结果与结论:①北美临床试验注册中心关于纳米给药系统在肿瘤靶向治疗的相关临床试验研究开始于1999年,共检索到注册项目489项,经查阅后,共有429项纳入了分析。美国注册的纳米载体肿瘤靶向给药临床试验项目最多,共112项,其次为加拿大24项。中国注册的临床试验有22项,其中大陆注册8项,香港地区注册4项,台湾地区注册10项。研究的注册数量2003年跌至谷底,只有5项注册项目,之后数量大幅度升高,在2008年注册项目数量达到顶峰,为56项。2008年后,注册的项目数量处于波动状态。②北美临床试验注册中心纳米给药系统在肿瘤靶向治疗的相关临床试验项目样本量在1-2000之间,以50人以下的小样本研究为主。研究的肿瘤类型以乳腺癌为主,其次为内分泌腺瘤及淋巴瘤。③2000-01-01/2012-12-31在Web of Science数据库发表的纳米载体肿瘤靶向给药相关文章4497篇,其中,美国发文量占总数比重最大(66.42%),发表文章2987篇。高被引文章主要发表在Proceedings of the National Academy of Sciences of the United States of America(《美国科学院院刊》)。展开更多
In this paper, we show that if rings A and B are （s, 2）-rings, then so is the ring of a Morita Context（[[A^S,≤]],[[B^S,≤]],[[M^S,≤]],[[N^S,≤]],ψ^S,Ф^S）of generalized power series. Also we get analogous resul...In this paper, we show that if rings A and B are （s, 2）-rings, then so is the ring of a Morita Context（[[A^S,≤]],[[B^S,≤]],[[M^S,≤]],[[N^S,≤]],ψ^S,Ф^S）of generalized power series. Also we get analogous results for unit 1-stable ranges, GM-rings and rings which have stable range one. These give new classes of rings satisfying such stable range conditions.展开更多
基金This research is supported by the National Natural Science Foundation of China (19801012)the Ministry of Education of China([2000]65)
文摘When R satisfies (strong unit) 1-stable range and M is a R-R-bimodule, the authors calculate that K_1(R(?) M)≌U(R(?) M)/L(R(?) M). As applications, the authors also calculate some Whitehead groups for exchange rings with artinian primitive factors.
文摘背景:纳米材料是抗肿瘤药物的理想载体,具有重要的科学价值和应用价值,为临床抗肿瘤提供了新的有效手段。目的:系统评价纳米给药系统在肿瘤靶向治疗的基础研究及临床应用。方法:以"nanoparticle,cancer,drug delivery system,nanotube,nanosphere"为关键词,计算机检索北美临床试验注册中心及Web of Science数据库2000-01-01/2012-12-31发表的纳米给药系统在肿瘤靶向治疗相关临床试验注册项目及文献。根据纳入与排除标准筛选文献,将检索结果以注册号、注册题目、项目状态、干预措施、试验的申办者、试验的疾病种类导出进行评价质量及文献分析。结果与结论:①北美临床试验注册中心关于纳米给药系统在肿瘤靶向治疗的相关临床试验研究开始于1999年,共检索到注册项目489项,经查阅后,共有429项纳入了分析。美国注册的纳米载体肿瘤靶向给药临床试验项目最多,共112项,其次为加拿大24项。中国注册的临床试验有22项,其中大陆注册8项,香港地区注册4项,台湾地区注册10项。研究的注册数量2003年跌至谷底,只有5项注册项目,之后数量大幅度升高,在2008年注册项目数量达到顶峰,为56项。2008年后,注册的项目数量处于波动状态。②北美临床试验注册中心纳米给药系统在肿瘤靶向治疗的相关临床试验项目样本量在1-2000之间,以50人以下的小样本研究为主。研究的肿瘤类型以乳腺癌为主,其次为内分泌腺瘤及淋巴瘤。③2000-01-01/2012-12-31在Web of Science数据库发表的纳米载体肿瘤靶向给药相关文章4497篇,其中,美国发文量占总数比重最大(66.42%),发表文章2987篇。高被引文章主要发表在Proceedings of the National Academy of Sciences of the United States of America(《美国科学院院刊》)。
基金Foundation item： the Natural Science Foundation of Hunan Province （No. 06jj20053） the Scientific Research Fund of Hunan Provincial Education Department （Nos. 06A017 07C268）.Acknowledgements The author would like to thank the referees for excellent suggestions and corrections leading to the new version of Lemma 2.8, which considerably improved the first version of the paper.
文摘In this paper, we show that if rings A and B are （s, 2）-rings, then so is the ring of a Morita Context（[[A^S,≤]],[[B^S,≤]],[[M^S,≤]],[[N^S,≤]],ψ^S,Ф^S）of generalized power series. Also we get analogous results for unit 1-stable ranges, GM-rings and rings which have stable range one. These give new classes of rings satisfying such stable range conditions.
